MAXCYTE, INC. (MXCT) Form 8-K — Aug 12, 2026
$MXCTForm 8-KItems 2.02, 7.01, 9.01Filed Aug 12, 2026, 4:14 PM ET0001104659-26-094886Original filing
MaxCyte reported second quarter 2026 total revenue of $7.3 million, down 15% year over year, with core revenue of $6.5 million down 21%, while the quarterly net loss narrowed to $8.9 million from $12.4 million a year earlier. CEO Maher Masoud said results were ahead of expectations, driven by instrument placements and stability in processing assembly sales.
Key figures
- Revenue
- 7271000
- Guidance
- FY2026 revenue of $30M-$32M (core revenue $25M-$27M; SPL Program-related revenue ~$5M, including ~$3M milestones and ~$2M commercial royalties); expects to end 2026 with at least $130.5M in total cash, cash equivalents and investments, excluding further buyback deployment
- Revenue Yoy
- -15%
- Total Assets
- 184672000
- Cash Position
- 141900000
- Shares Outstanding
- 106134011
- Royalties q2
- 764000
- Royalties yoy
- +150%
- H1 2026 revenue
- 16922000
- Core revenue yoy
- -21%
- Clinical programs
- 12
- Gaap gross margin
- 77%
- Commercial programs
- 1
- Core revenue q2 2026
- 6503000
- Total spl agreements
- 29
- Operating expenses q2
- 15828000
- Share repurchases to date
- 5500000
- Installed base instruments
- 899
- Stock based compensation q2
- 1200000
- Non gaap adjusted gross margin
- 77%
- Precommercial milestone potential
- approximately $110M
- Share repurchase program authorized
- 10000000
Price after filing
1 day: +9.4%7 days: +9.4%30 days: -8.7%
Close on the filing date to close N calendar days later (from $1.27). Historical, not a forecast.
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.